NASDAQ:ORIC Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis $10.26 +0.41 (+4.16%) Closing price 08/27/2025 04:00 PM EasternExtended Trading$10.28 +0.03 (+0.24%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Oric Pharmaceuticals Stock (NASDAQ:ORIC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oric Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.83▼$10.2650-Day Range$9.20▼$11.8052-Week Range$3.90▼$14.67Volume1.16 million shsAverage Volume750,770 shsMarket Capitalization$996.45 millionP/E RatioN/ADividend YieldN/APrice Target$17.63Consensus RatingModerate Buy Company Overview ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Read More Oric Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks96th Percentile Overall ScoreORIC MarketRank™: Oric Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 53rd out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingOric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOric Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Oric Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Oric Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oric Pharmaceuticals is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oric Pharmaceuticals is -5.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOric Pharmaceuticals has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oric Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.51% of the float of Oric Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOric Pharmaceuticals does not currently pay a dividend.Dividend GrowthOric Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.16 Percentage of Shares Shorted8.51% of the float of Oric Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.06 News SentimentOric Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Oric Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest4 people have searched for ORIC on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows12 people have added Oric Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oric Pharmaceuticals insiders have sold 58.30% more of their company's stock than they have bought. Specifically, they have bought $262,976.00 in company stock and sold $416,289.00 in company stock.Percentage Held by InsidersOnly 6.82% of the stock of Oric Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oric Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORIC Stock News HeadlinesOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $17.63 Consensus Target Price from BrokeragesAugust 28 at 2:13 AM | americanbankingnews.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 27 at 4:05 PM | globenewswire.comChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in America could soon begin to replace every single dollar in your bank account… With a better, more technologically advanced dollar… Potentially making a lot of people rich in the process.August 28 at 2:00 AM | Brownstone Research (Ad)This ORIC Pharmaceuticals Insider Increased Their Holding In The Last YearAugust 24, 2025 | finance.yahoo.comORIC Pharmaceuticals: ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical OfficerAugust 19, 2025 | finanznachrichten.deORIC Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comOric Pharmaceuticals appoints Kevin Brodbeck CTOAugust 19, 2025 | msn.comORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical OfficerAugust 18, 2025 | globenewswire.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? Oric Pharmaceuticals' stock was trading at $8.07 at the beginning of 2025. Since then, ORIC stock has increased by 27.1% and is now trading at $10.26. How were Oric Pharmaceuticals' earnings last quarter? Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01. When did Oric Pharmaceuticals IPO? Oric Pharmaceuticals (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. Who are Oric Pharmaceuticals' major shareholders? Top institutional investors of Oric Pharmaceuticals include Alkeon Capital Management LLC (4.64%), Vivo Capital LLC (3.67%), Balyasny Asset Management L.P. (1.83%) and MPM Bioimpact LLC (1.78%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You. View institutional ownership trends. How do I buy shares of Oric Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oric Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings8/12/2025Today8/28/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORIC CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for Oric Pharmaceuticals$17.63 High Price Target$20.00 Low Price Target$12.00 Potential Upside/Downside+71.8%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.75% Return on Assets-47.09% Debt Debt-to-Equity RatioN/A Current Ratio16.13 Quick Ratio16.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book3.07Miscellaneous Outstanding Shares97,120,000Free Float90,499,000Market Cap$996.45 million OptionableOptionable Beta1.69 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ORIC) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.